EB-1020 Sustained Release
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for EB-1020 Sustained Release, covering 2021-10-18 to 2021-10-18. Get the full timeline:
Most recent: Clinical Trial Update: Study of Flexible Doses of the Triple Reuptake Inhibitor EB-1020 Sustained Release (SR) in the Treatment of Adult Males With Attention-Deficit Hyperactivity Disorder [Phase 2]